Connection between ACPA (Anti-Citrullinated Protein Antibodies) and Rheumatoid Arthritis: Essential Information

Connection between ACPA (Anti-Citrullinated Protein Antibodies) and Rheumatoid Arthritis: Essential Information

In the world of autoimmune diseases, rheumatoid arthritis (RA) grips countless individuals, often without warning. Sounding the alarm, our immune system produces these pesky little things called anti-citrullinated protein antibodies (ACPAs). Let's talk about these buggers and how they impact our battle against RA.

RA, a condition where our immune system attacks our own tissues, can leave us in painful, swollen, and stiff joint states. But what triggers our immunity to go rogue? Well, the immune system fires up some chemical agents called antibodies to target tissues—and the ACPA is one such chemical agent. This bad boy disrupts specific cell processes and can spark a vicious cycle of damage and autoimmune activity that contributes to RA.

So, if you've got ACPAs, does it mean you have RA? Not necessarily. A 2021 literature review shares that a positive ACPA test can be considered a specific biological sign of RA—but it's not a definitive diagnosis. Levels of another antibody called rheumatoid factor (RF) can also indicate RA. Doctors may weigh levels of both these antibodies when diagnosing RA, as they help paint a picture of disease progression and outlook.

For example, if both ACPA and RF tests are positive, you're likely looking at a case of RA and may be facing more aggressive symptoms. However, a positive ACPA test without a positive RF may signify early RA or an increased risk of developing it in the future. But don't freak out if both tests come back negative; you might still have RA based on other criteria or symptoms, and you could develop ACPAs over time.

Things can get a touch confusing, though. If your tests are positive for ACPAs but you have a different autoimmune condition like systemic lupus erythematosus (SLE) or Sjögren disease, that's pretty rare.

Now, when we talk about RA with and without ACPAs, what's the difference? A 2022 study involving 198 people with RA found that those with ACPA-positive RA had consistently low levels of joint inflammation during periods of remission, but those with ACPA-negative RA responded more to treatment with disease-modifying antirheumatic drugs (DMARDs) in the first year of therapy.

Additionally, this study suggests that people with ACPA-negative RA in remission have similar inflammation levels to those without RA, while those with ACPA-positive RA who move into remission have significantly lower inflammation levels from the point of diagnosis onward.

Some studies also indicate that ACPA-positive RA patients might suffer more severe bone erosion, often in the fifth metatarsophalangeal joint (little toe joint), and are more influenced by environmental risk factors like smoking.

But where do ACPAs come from? They're produced by our ever-so-helpful immune system in response to a process called citrullination. Citrullination happens when an enzyme called peptidylarginine deiminase (PAD) transforms arginine (a protein building block called an amino acid) into another amino acid, citrulline.

This process occurs in several places, like brain development, skin health, and the natural death of cells, but in people with RA, it happens too much. Specific proteins that undergo citrullination include collagen, an essential part of connective tissue, tendons, and ligaments that RA can affect. Cell damage can lead to PAD working overtime, causing excess citrullination, and the immune system responds by producing ACPAs to attack these citrullinated proteins.

This feedback loop can escalate inflammation and tissue damage in people with RA, with smoking or air pollution potentially worsening the situation.

So, how do wizards in white coats (i.e., doctors) identify these devious ACPAs? With a simple blood test for cyclic citrullinated peptides (CCP), a type of ACPA. This test lasts no more than 5 minutes and can help a physician diagnose or rule out RA.

However, conditions like SLE, Sjögren disease, tuberculosis (TB), and chronic lung disease can also cause elevated CCP antibodies. So, the doctor will consider your medical history, physical exam, and the results of other tests when diagnosing RA.

And even after RA is diagnosed, doctors often test for other antibodies to confirm the diagnosis, including antinuclear antibody, C-reactive protein, RF, and synovial fluid analysis, and may request X-rays of the joints to assess damage.

Last but not least, it's worth noting the distinction between ACPAs and CCP antibodies. Anti-cyclic citrullinated peptides (anti-CCP) antibodies are a type of ACPA. Anti-CCP antibodies react to cyclic citrullinated peptides (CCPs) like fibrinogen or myelin basic protein, but react differently to each, whereas ACPAs can react to more than just CCPs.

1. Rheumatoid arthritis (RA) is an autoimmune disease that attacks one's own tissues, causing joint pain, swelling, and stiffness.
2. Anti-citrullinated protein antibodies (ACPAs) are chemical agents produced by the immune system in RA, targeting specific cell processes and contributing to damage and autoimmune activity.
3. A positive ACPA test can be a sign of RA, but not a definitive diagnosis; rheumatoid factor (RF) levels can also indicate RA.
4. If both ACPA and RF tests are positive, it's likely a case of RA with potentially more aggressive symptoms. A positive ACPA test without a positive RF may suggest early RA or an increased risk of developing it.
5. ACPAs are produced by the immune system in response to citrullination, a process involving an enzyme called peptidylarginine deiminase (PAD) that converts arginine to citrulline, affecting proteins like collagen and sparking the immune response.
6. Doctors use a simple blood test for cyclic citrullinated peptides (CCP), a type of ACPA, to diagnose or rule out RA, though other medical conditions can cause elevated CCP levels.
7. In the treatment of RA, disease-modifying antirheumatic drugs (DMARDs) may be more effective for ACPA-negative RA patients during the first year of therapy, while those with ACPA-positive RA have lower inflammation levels during remission.

Read also: